Postmenopausal hormone drugs and breast and colon cancer: Nordic countries 1995-2005

Maturitas

Volumn 61, Issue 4, 2008, Pages 299-304

  Hemminki, Elina ^a,c   Kyyrönen, Pentti ^b   Pukkala, Eero ^b  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b FINNISH CANCER REGISTRY   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Breast cancer; Colon cancer; Postmenopausal hormone therapy

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER REGISTRY; COLON CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FINLAND; HORMONAL THERAPY; HUMAN; ICELAND; MAJOR CLINICAL STUDY; NORWAY; POSTMENOPAUSE; SWEDEN;

BREAST NEOPLASMS; COLONIC NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; ICELAND; INCIDENCE; MIDDLE AGED; POSTMENOPAUSE; REGISTRIES; SCANDINAVIA;

EID: 57849087666     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2008.09.022     Document Type: Article

References (31)

1. Chlebowski R., Hendrix S.L., Langer R.D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women's health initiative randomized trial. JAMA 289 (2003) 3243-3253
2. Chlebowski R.T., Wactawski-Wende J., Ritenbaugh C., et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 350 (2004) 991-1004
3. Stefanick M.L., Anderson G.L., Margolis K.L., et al., for the WHI Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295 (2006) 1647-1657
4. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
5. Clarke C.A., Glaser S.L., Uratsu C.S., Selby J.V., Kushi L.H., and Herrinton L.J. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 24 (2006) 49e-50
6. Robbins A.S., and Clarke C.A. Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol 25 (2007) 3437-3439
7. Glass A.G., Lacey J.V., Carreon J.D., and Hoover R.N. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 99 (2007) 1152-1161
8. Ravdin P.M., Cronin K.A., Howlader N., et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356 (2007) 1670-1674
9. Katalinic A., and Rawal R. Decline in breast cancer incidence after decrease in utilization of hormone replacement therapy. Breast Cancer Res Treat 107 (2008) 427-430
10. Collaborative group on hormonal factors in breast cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108,411 women without breast cancer. Lancet 350 (1997) 1047-1059
11. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002; Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5, version 2.0. Lyon: IARC Press; 2004.
12. Engholm G, Storm H, Ferlay J et al. Cancer incidence and mortality in the Nordic countries, version 2.2. Association of the Nordic Cancer Registries, 2006. Electronic publication http://www.ancr.nu/nordcan.asp.
13. NOMESCO. Medicines consumption in the Nordic Countries 1999-2003. NOMESCO Nordic Medico Statistical Committee 72: Copenhagen 2004.
14. Helakorpi S., Patia K., Prättälä R., and Uutela A. Health behavior and health among the Finnish adult population, spring publications of the National Public Health Institute 18/2005 2 (2005), National Public Health Institute, Helsinki 21
15. Anttila A., Sarkeala T., Hakulinen T., and Heinävaara S. Impacts of the Finnish service screening programme on breast cancer rates. BMC Public Health 8 (2008) 38
16. Hofvind S., Geller B., Vacek P.M., Thoresen S., and Skaane P. Using the European guidelines to evaluate the Norwegian breast cancer screening program. Eur J Epidemiol 22 (2007) 447-455
17. Sarkeala T., Heinävaara S., and Anttila A. Organised mammography screening reduces breast cancer mortality: a cohort study from Finland. Int J Cancer 122 (2008) 614-619
18. Hemminki K., Rawal R., and Bermejo J.L. Mammographic screening is dramatically changing age-incidence data for breast cancer. J Clin Oncol 22 (2004) 4652-4653
19. Lyytinen H., Pukkala E., and Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gyncecol 108 (2006) 1354-1360
20. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 (2003) 419-427
21. Haas J.S., Kaplan C.P., Gerstenberger E.P., and Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 140 (2004) 184-188
22. Hersh A.L., Stefanik M.L., and Stafford R.S. National use of postmenopausal hormone therapy. JAMA 291 (2004) 47-53
23. Lawton B., Rose S., McLeod D., and Dowell A. Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of users. BMJ 327 (2003) 845-846
24. Mishra G., Kok H., Ecob R., Cooper R., Hardy R., and Kuh D. Cessation of hormone replacement therapy after reports of adverse findings from randomized controlled trials: evidence from a British birth cohort. Am J Public Health 96 (2006) 1219-1225
25. MacLennan A.H., Taylor A.W., and Wilson D.H. Hormone therapy use after the Women's Health Initiative. Climacteric 7 (2004) 117-119
26. Austin P.C., and Karen T. Prescriptions for estrogen replacement therapy in Ontario before and after publication of the Women's Health Initiative Study. JAMA 289 (2003) 3241-3242
27. Du Y., Doren M., Melchert H.U.W., Scheidt-Nave C., and Knopf H. Differences in menopausal hormone therapy use among women in Germany between 1998 and 2003. BMC Women's Health 7 (2007) 19
28. Hulley S., Gardy D., Bush T., et al., for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 (1998) 605-613
29. Hoffmann M., Hammar M., Kjellgren K.I., Lindh-Åstrand L., and Brynhildsen J. Changes in women's attitudes towards the use of hormone therapy after HERS and WHI. Maturitas 52 (2005) 11-17
30. Hemminki E. Opposition to unpopular research results: Finnish professional reactions to the WHI findings. Health Policy 69 (2004) 283-291
31. Moen M.H., Nilsen S.T., and Iversen O.E. A significant change in Norwegian gynecologists' attitude to hormone therapy is observed after the results of the Women's Health Initiative study. Acta Obstet Gynecol Scand 84 (2005) 92-93